
LUMO
Healthcare · Biotechnology · $37.5M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2024
EPS trend, 90 days to now · +11.8% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 5, 2024 | Before the open | -0.76 | -0.90 | -18.4% |
| Aug 1, 2024 | After the close | -1.24 | -0.93 | +25.0% |
| May 14, 2024 | After the close | -1.18 | -1.29 | -9.3% |
| Mar 7, 2024 | After the close | -1.15 | -1.17 | -1.7% |
| Nov 7, 2023 | After the close | -1.15 | -1.04 | +9.6% |
| Aug 9, 2023 | After the close | -1.10 | -1.09 | +0.9% |
| May 3, 2023 | After the close | -1.12 | -0.89 | +20.5% |
| Mar 1, 2023 | After the close | -0.93 | -0.99 | -6.5% |
| Nov 14, 2022 | Before the open | -1.01 | -0.86 | +14.9% |
| Aug 9, 2022 | After the close | -0.99 | -0.94 | +5.1% |
| May 10, 2022 | After the close | -0.89 | -0.92 | -3.4% |
| Mar 10, 2022 | After the close | -0.92 | -0.67 | +27.2% |
| Nov 3, 2021 | After the close | -1.07 | -0.90 |
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare…
| +15.9% |
| Aug 5, 2021 | Before the open | -1.03 | -1.04 | -1.0% |
| May 5, 2021 | After the close | -0.87 | -1.04 | -19.5% |
| Mar 9, 2021 | After the close | -0.86 | -0.31 | +64.0% |
| Nov 10, 2020 | After the close | -0.64 | 0.21 | +132.8% |
| Aug 13, 2020 | After the close | -0.71 | -0.65 | +8.5% |
| May 28, 2020 | After the close | -0.82 | -0.14 | +82.9% |
| Feb 28, 2020 | Before the open | -2.52 | -1.98 | +21.4% |
| Nov 6, 2019 | Before the open | -2.43 | -2.43 | 0.0% |
| Jul 30, 2019 | Before the open | -2.61 | -2.43 | +6.9% |
| May 8, 2019 | After the close | -2.74 | -2.43 | +11.3% |
| Feb 27, 2019 | After the close | -3.09 | -2.52 | +18.4% |
| Nov 1, 2018 | After the close | -3.60 | -1.80 | +50.0% |
| Jul 31, 2018 | After the close | -5.42 | -4.23 | +22.0% |
| May 3, 2018 | After the close | -4.95 | -4.41 | +10.9% |
| Mar 1, 2018 | After the close | -6.03 | -3.33 | +44.8% |